Indications
Crisaborole is a medicine you apply to the skin for mild to moderate atopic dermatitis. It can be used in children from 3 months of age and older.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Crisaborole is a phosphodiesterase-4 (PDE-4) inhibitor. It acts mainly on phosphodiesterase 4B (PDE4B), the enzyme linked to inflammation. Chemically, Crisaborole is a phenoxybenzoxaborole, and it carries a boron atom. That boron helps the medicine penetrate the skin and is essential for its binding activity.
When PDE4B is inhibited, the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines appears to be suppressed. These cytokines are proteins believed to be involved in the immune response and inflammation.
Pregnancy & Breastfeeding
Pregnancy: No data are available on the use of Crisaborole in pregnant women, so the risk of major birth defects and miscarriage linked to the medicine is not known. In animal reproduction studies, crisaborole was given by mouth to pregnant rats and rabbits during organogenesis, at doses up to 3 and 2 times, respectively, the maximum recommended human dose (MRHD). No adverse effects on development were seen.
Lactation: There is no information on whether crisaborole passes into human milk. The medicine is absorbed into the body (systemically absorbed). Because clinical data during breastfeeding are lacking, the risk of crisaborole to a breastfed infant can't be clearly determined.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.